Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

PDUFA VI: NORD Wants Reviewers To Be More Accessible

Aug 18 2016

• By Derrick Gingery

business

Related Content

Group Submits Duchenne Muscular Dystrophy Guidance, Hoping To Direct FDA Policy

Jul 07 2014

Rare Disease Integration Into FDA Reviews Will Grow Under PDUFA VI

Jul 18 2016

FDA Quietly Consults Patients To Understand <em>Vimizim's</em> Six-Minute Walk Significance

Dec 01 2014

FDA’s Patient-Focused Drug Development Meetings Inspire Imitators

May 19 2014

Patient-Focused Drug Development At 10: Where Does It Go From Here?

Oct 20 2014

Rare Disease Products Mostly Approved With Regulatory Flexibility, NORD "Catalog" Finds

Oct 11 2011

FDA's Breakthrough Workload Will Be Eased By Hiring Reviewers With PDUFA VI Funds

Jul 21 2016

You Just Have To Wait: FDA Can't Hurry PDUFA VI Guidances

Aug 15 2016

Additional Topics

United States Clinical Trials Drug Review Policy BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window